[{"Assets_0_Q3_USD":2105742000.0,"CommonStockSharesOutstanding_0_Q3_shares":21095174.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":161487000.0,"NetIncomeLoss_1_Q3_USD":67362000.0,"NetIncomeLoss_3_Q3_USD":185803000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":24052416.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":24429571.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":21148000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":21189000.0,"StockholdersEquity_0_Q3_USD":699520000.0,"EarningsPerShareBasic_1_Q3_USD":3.19,"EarningsPerShareBasic_3_Q3_USD":8.77,"EarningsPerShareDiluted_1_Q3_USD":2.8,"EarningsPerShareDiluted_3_Q3_USD":7.61,"Ticker":"LGND","CIK":"886163","name":"LIGAND PHARMACEUTICALS INC","OfficialName":"Ligand Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1738856427.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181108"}]